deuterated dextromethorphan
Small moleculeexperimental
Clinical trial activity
18 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
12
Phase 3
8
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01787747)
Timeline
Indications
Studied for
- Alzheimer Disease · Phase 3
- Attention Deficit and Disruptive Behavior Disorders · Phase 2
- Depression · Phase 3
- Depressive Disorder, Treatment-Resistant · Phase 2
- Disruptive, Impulse Control, and Conduct Disorders · Phase 2
- Drug Interactions · Phase 1
- Healthy Volunteers · Phase 1
- Major Depressive Disorder · Phase 3
- Psychological Distress · Phase 2
- Psychomotor Agitation · Phase 3
- Schizophrenia · Phase 2/Phase 3
Mechanism of action
- Glutamate (NMDA) receptor subunit zeta 1ANTAGONIST
Glutamate (NMDA) receptor subunit zeta 1 antagonist
- Sigma opioid receptorINHIBITOR
SIGMAR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- avp-786
- avp-786
- axs-05
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04464564 | Phase 3 | Sep 3, 2020 | Avanir |
| NCT04408755 | Phase 3 | Jun 15, 2020 | Avanir |
| NCT03896945 | Phase 2/Phase 3 (Phase 3) | Feb 15, 2019 | Avanir |
| NCT03420222 | Phase 2 | Jan 1, 2018 | Avanir |
| NCT03393520 | Phase 3 | Oct 13, 2017 | Avanir |
| NCT03095066 | Phase 2 | May 30, 2017 | Avanir |
| NCT02741791 | Phase 3 | Mar 1, 2016 | Axsome Therapeutics, Inc. |
| NCT02534038 | Phase 2 | Dec 1, 2015 | Avanir |
| NCT02446132 | Phase 3 | Dec 1, 2015 | Avanir |
| NCT02477670 | Phase 2 | Sep 1, 2015 | Avanir |
| NCT02442765 | Phase 3 | Sep 1, 2015 | Avanir |
| NCT02442778 | Phase 3 | Sep 1, 2015 | Avanir |
| NCT02402595 | Phase 1 | Mar 1, 2015 | Avanir, Vince & Associates |
| NCT02153502 | Phase 2 | Jul 1, 2014 | Avanir |
| NCT02336347 | Phase 1 | May 1, 2014 | Avanir |
| NCT02174822 | Phase 1 | Jan 1, 2014 | Avanir, Nucleus Network Ltd |
| NCT02174835 | Phase 1 | Sep 1, 2013 | Avanir, IDT Australia Ltd. |
| NCT01787747 | Phase 1 | Oct 1, 2012 | Avanir, IDT Australia Ltd. |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avanir | For profit | 17 | 17 | 3 | 2012 |
| IDT Australia Ltd. | For profit | 2 | 0 | 1 | 2012 |
| Axsome Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2016 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2014 |
| Vince & Associates | For profit | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1